Thank you operator. Good afternoon everyone, and thank you for joining us. With me on today's call is Mike Rice, Chairman and Chief Executive Officer. Earlier today, we issued a press release announcing our preliminary unaudited financial results and operational highlights for the fourth quarter and full year 2022, which is available at biolifesolutions.com. As a reminder, during this call, we will make certain projections and other forward-looking statements regarding future events or the future financial performance of the company. These statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. For a detailed discussion of the risks and uncertainties that affect the company's business and that qualify as forward-looking statements, I refer you to our periodic reports and other public filings filed with the SEC. Company projections and forward-looking statements are based on factors that are subject to change, and therefore, these statements speak only as of the date they are given. The company assumes no obligation to update any projection or forward-looking statements except as required by law. During this call, we will speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. These non-GAAP or adjusted financial metrics should not be viewed as an alternative to GAAP. However, in light of our historic M&A activity, we believe that the use of non-GAAP or adjusted metrics provides investors with a clear view of our current financial results when compared to prior periods. Now, I'd like to turn the call over to Mike Rice, Chairman and Chief Executive Officer of BioLife Solutions. Thanks, Troy. Good afternoon, everyone. Thank you for joining our call. After my remarks, Troy will present our financials for Q4 and the full year of 2022. After that, we'll be glad to take your questions. I'll start off by noting the strong performance our team delivered in Q4 to conclude 2022 with continued execution on our key initiatives of gaining new CGT and biopharma customers, driving continued adoption of our cell processing and storage services platforms, and making meaningful supply chain and quality improvements in our freezers platform. Turning to Q4 revenue and customer highlights, while some of our peers in the life science tool space cited some segment headwinds, for the most part, we didn't experience any significant negative impact in the quarter. Total revenue was $44.3 million, up 21% from Q4 2021, with organic revenue growth of 18%. A key highlight of Q4 was cell processing platform revenue growth of 36%. Our growth catalyst and business fundamentals for our high growth, high margin, recurring revenue streams remain intact. To make the point on revenue differentiation in Q4, about 60% of total revenue was recurring high margin, with instruments comprising the rest. As a reminder, we expect this to increase to 70% or more by the end of 2025. In Q4, we sold and shipped products or provided services to 217 new unique customer sites across our three product and services platforms. Most of our revenue comes from existing customers as we penetrate deeper and pitch our integrated solutions to take more share of their spend for manufacturing, storage, and distribution, tools and services. In each of the four quarters of 2022, we gained about 200 new customer sites, building a phenomenal pipeline of early-stage customers that we will nurture and support to drive future growth. I'll remind you now what our three platforms are. First, cell processing, which includes biopreservation media and Sexton cell processing products. Second is our freezers and thaw systems platform, comprised of cryogenic liquid nitrogen freezers, Stirling ULT mechanical freezers, and automated thawing instruments. Finally, storage and storage services, which includes SciSafe storage services and our EVO cold chain management offering. New Q4 customer sites by product line included 15 now using biopreservation media, seven new ThawSTAR users, 12 new EVO cold chain end users, 13 new cryogenic freezers and accessories customers, 139 new Stirling ULT freezer and accessory customers, 26 new Biostorage customers, and five new cell processing customers now using Sexton products. For cell processing in Q4, we received confirmation that our solutions will be used in at least 27 additional clinical trials for new cell or gene therapies. We estimate that our biopreservation media products have been used in or are planned to be used in over 600 customer clinical applications. For biopreservation media, we also remain confident that each customer clinical application, if approved, could generate annual revenue in a range of $500,000-$2 million. To date, BioLife products and solutions are being used in 12 approved therapies, which includes use of our Sexton cell processing media and vials in three approved therapies, including Breyanzi from BMS, Abecma from ReoCell, and Carteyva from JW Therapeutics. Note, all of these approved therapies also use our CryoStor biopreservation media. Our biopreservation media products are also embedded in at least 10 additional anticipated approvals by the end of 2024. I will conclude by saying that our biopreservation media clinical customer base includes most of the CAR T-cell developers, with our proprietary products embedded in a majority of the autologous and allogeneic platforms currently in development. We expect to be able to continue to take share from homebrew preservation cocktails as awareness grows of the critical role our engineered media formulations play in reducing risk for CGT companies. We see five strong catalysts that can support our growth estimates by increasing the total manufactured doses that our solutions are embedded in. These are approval of new cell and gene therapies, approvals of existing commercial therapies as first or second line treatment, approvals of existing commercial therapies for additional indications, approval of existing commercial therapies in new geographies, and finally, an eventual shift to allogeneic therapies. For the other part of our cell processing platform, our Sexton products, adoption in customer clinical applications include 67 using HPL media, 61 using CellSeal vials, and two using automated fill machines. As you can see, we're running our biopreservation media playbook to drive adoption of Sexton products. We estimate that annual revenue for Sexton reagents and consumables used in approved customer therapies also ranges from $500,000-$2 million for both CellSeal and HPL media. Turning to our freezers and thaw systems platform, we shipped first-time orders to 159 new customer sites. Customers continue to see the value proposition of our Stirling ULT freezer offering based on tight temperature regulation, reduced power consumption, reduced heat generation, and less noise pollution, as these support their goal of reducing the negative environmental impact of their operations. In our final of three revenue platforms, storage and storage services, which includes EVO cold chain rentals and SciSafe storage services, we either shipped first-use products or engaged for initial services with 38 new customer sites in Q4, 26 for storage services and 12 for EVO. With our EVO cold chain management platform, cell and gene therapy companies now have broad access to our class-defining offering through our expanded specialty courier partner network that now includes SciSafe, World Courier, Quick International, Thermo Fisher, Marken, and Biocair. We believe we can continue to drive our EVO platform to become a meaningful revenue and profit contributor. Q4 EVO shipments of over 2,000 were up well over 100% over the same quarter last year. Of these, we estimate approximately 75% were for approved therapies and the rest were for clinical trials. Total EVO shipments for the full year 2022 were nearly 10,000. A doubling over 2021. We're collecting a huge amount of shipment information that is shaping our innovation and development of our transport containers and EVO IS cloud app. We are focused on giving our courier partners and end CGT customers even more actionable data to reduce risk. We continue to support validations by additional CGT companies with approved therapies. Based on our force multiplying courier network, we believe that the EVO platform will increasingly be selected as a class-defining temperature-controlled shipping container and related cloud app by the leading CGT companies. To wrap up new customers acquired in 2022, the full year estimates by product and service line include 69 for biopreservation media, 33 for Sexton cell processing solutions, 99 for SciSafe storage services, 43 for EVO cold chain management, 82 for cryogenic freezers, 461 for ULT freezers, and 35 for thaw systems. Additionally, to illustrate the reach of our largest media distributor, STEMCELL Technologies, in 2022, they sold and shipped our products to more than 3,000 unique end users, more than 500 of these were first-time users of our products. Turning now to an update on our continued work to improve operations, margin, and quality at Stirling, our team is focused on supply chain optimization, reducing scrap, and improving efficiency in the plant to right-size the workforce with a focus on getting things done right the first time. We're shipping from inventory, our quality metrics are at an all-time high level. Now I'll turn the call back over to Troy to present our financials for Q4 and the full year 2022. Troy? Thank you, Mike. Total revenue for the fourth quarter of 2022 totaled a record $44.3 million, representing a total increase of 19% and organic increase of 18% over Q4 of 2021, driven by a 35% increase in biopreservation media revenue. COVID-19 related revenue accounted for approximately 5% of total revenue in the quarter versus 15% in Q4 2021. Cell processing platform revenue was $20.2 million. Total revenue increased 36%, and organic revenue increased 35% over the same period in 2021. Freezers and thaw systems platform revenue was $17.4 million. Total and organic revenue was up 5% over the same period in 2021. COVID-19 related revenue accounted for approximately 3% of the freezer and thaw systems platform revenue versus 15% in Q4 2021. Storage and storage services platform revenue was $6.7 million, with both total and organic growth of 14% over the same period in 2021. COVID-19 related revenue accounted for approximately 21% of the storage and storage services platform revenue versus 50% in Q4 2021. Total revenue for the full year 2022 was $161.8 million. Total revenue increased 36%, and organic revenue increased 38% over 2021. COVID-19 related revenue was approximately 8% compared with approximately 15% in 2021. Adjusted gross margin for the fourth quarter of 2022 was 32% compared with 17% for the fourth quarter of 2021. For the full year of 2022, adjusted gross margin was 33% compared with 32% in 2021. The Q4 2022 adjusted gross margin was impacted by a late Q3 2022 stock grant to the operational team, which increased approximately $1 million over Q3 2022, or 2.3 percentage points of Q4 2022 revenue. In addition, we had unfavorable product and customer mix at our LN2 freezer line, inventory write-off charges, and a decrease in SciSafe COVID-19 related revenue without an associated decrease of infrastructure costs. We expect adjusted gross margin to improve in 2023 versus 2022. GAAP operating expenses for Q4 2022 were $93.5 million, which includes an intangible impairment of $40.5 million related to the Global Cooling acquisition versus $54.9 million in Q4 2021. The non-cash impairment to the Global Cooling intangible assets in Q4 resulted primarily from changes in our revenue assumptions due to updated estimates for customer capital spending in the current macroeconomic environment, as noted by some of our competitors in Q3 and Q4 of 2022, and longer than expected inflationary pressures on raw materials. For the full year of 2022, GAAP operating expenses were $307.3 million, which includes non-cash intangible impairments totaling $110.4 million in Q2 and Q4 of 2022 related to the Global Cooling acquisition, compared with full year 2021 GAAP operating expenses of $154.3 million. Adjusted operating expenses for Q4 2022 were $22.1 million, compared with $19.2 million in Q4 2021. For the full year of 2022, adjusted operating expenses were $83.4 million, compared with $59.6 million in 2021. Full year 2022 adjusted operating expenses increased due to the 2021 acquisitions of Global Cooling and Sexton. Operating expenses increased in Q4 and full year 2022 due to higher accounting costs and increased headcount to support our growth. Adjusted operating loss for the fourth quarter of 2022 was $8.2 million, compared with adjusted operating loss of $13.1 million in the fourth quarter of 2021. Our adjusted operating loss for the full year of 2022 totaled $29.3 million, compared with adjusted operating loss of $21.5 million in 2021. Adjusted EBITDA for the fourth quarter of 2022 was positive $1.7 million, compared with negative $5.9 million for the fourth quarter of 2021. For the full year of 2022, adjusted EBITDA was positive $3.6 million, compared with positive $4.1 million in 2021. Our cash and marketable securities balance at December 31, 2022 was $64.1 million, compared with $61.7 million at September 30, 2022. Turning to our 2023 revenue guidance, which we are reaffirming from our January 9, 2023 preliminary revenue press release. Full year revenue is expected to be in the range of $188 million-$202 million, reflecting year-over-year and organic growth of 16%-25% and an expected split of 45% in the first half of the year and 55% in the second half. Excluding COVID-19 related revenue, year-over-year growth of 26%-35%. Revenue guidance for 2023 does not include any COVID-19 related revenue. Total revenue expectations for 2023 include the following platform contributions. Cell processing platform, $89 million-$93 million, an increase of 30%-35% over 2022. Freezers and thaw systems platform, $72.5 million-$79 million, an increase of 9%-18% over 2022. Excluding COVID-19 related revenue, year-over-year growth of 13%-23%. Storage and storage services platform, $26.5 million-$30 million, an increase of 0%-13% over 2022. Excluding COVID-19 related revenue, year-over-year growth of 64%-86%. Although the company does not provide guidance below the revenue line, we expect improvements in gross margin and adjusted EBITDA in 2023 compared to 2022. In terms of our share count, as of March 10th, 2023, we had 43.1 million shares issued and outstanding and 46.1 million shares on a fully diluted basis. I'd like to talk about 10b5-1 plans. As you may recall, several executives requested to be paid in stock in lieu of salary in 2022. Some executives entered 10b5-1 plans back in 2022 with planned sales upcoming in Q1 2023. These plans can't be changed, and sales are based on personal reasons and not related to the business outlook of BioLife. Lastly, I'd like to address our 10-K filing. Due to turnover at our corporate controller position in late Q4 and additional SOX requirements for in-scope entities Global Cooling and Sexton, we will be filing an extension this year. We will be filing for the automatic extension with the SEC, which gives us an extension of 15 calendar days from today to file our 10-K and still be considered timely. We expect to file within the extended period. Now I'll turn the call to Mike. Thanks, Troy. Now I'll summarize our key takeaways for 2022. First, BioLife Solutions is a critical, highly trusted tools and services provider to the cell and gene therapy industry. We built a valuable portfolio of solutions that can help CGT developers increase their likelihood of success by reducing risk in the manufacturing, storage, and distribution workflows. Number two, demand for our portfolio of class-defining bioproduction tools and services remains strong. Let's all remember that we're still in the early innings of CGT approvals, and we have hundreds of shots on goal. We continue to derive a mix shift to high margin recurring revenue anchored by our cell processing and storage services platforms. Number three, we made significant supply chain and quality improvements in 2022 and will continue to do so this year. Turning to 2023, we expect to continue to derive adoption of our solutions in the CGT space with our cell processing offerings embedded in up to 10 additional candidates that could get approved this year and next year. We remain confident that we will achieve our 2024 exit run rate aspirational financial goals of $250 million in revenue, 50 points of adjusted gross margin, and 30 points of adjusted EBITDA margin. I'll turn the call back over to the operator. Thank you. If you would like to ask a question on the phone lines today, you can press star one on your telephone keypad. If you would like to remove yourself from the queue, that is star one again. We'll take our first question from Jacob Johnson with Stephens. Hey, good evening, everybody. Troy, maybe just first on. Hey, Jacob. Hey. Hey, Mike. Good afternoon there. Just first for Troy or for you, Mike, just on the gross margin decline sequentially. I appreciate the items you called out, and I appreciate the 50% gross margin by 4Q 2024. Can you help us, you know, kind of bridge to that 50% and the key levers you can pull to achieve that? Also understanding you don't guide below the line, but could you maybe help us with how much gross margin you could realize in 2023 or what that could look like? Thanks. Hey, thanks, Jacob. I'll take the longer-term view, and maybe Troy can speak a little more about 2023. Our levers, to use your term, Jacob, about the bridge to margin aspirational goals are really based on 3 things as it relates to ULT. Again, as ULT is a fairly significant chunk of revenue, so that's meaningful. Those are to continue to optimize the supply chain and look for opportunities to reduce waste, improve productivity in the plant, but also, you know, on the top line, much better margin from new products and new service revenue streams that are related to freezers. Again, when we can speak more about that in detail, we surely will. Troy, do you want to speak at all about the last half of this year, where we expect the more meaningful margin improvements? Yeah. In addition to what Mike said, the SciSafe facilities too, throughout the year, we expect higher utilization, which has an impact on the gross margin. In light of that, we expect the margin expansion to be more weighted in the second half of the year versus the first half. As I mentioned in my remarks too, we had unfavorable product mix at our LN2 line, higher than expected scrap, and then again that COVID revenue at SciSafe dropping off had a pretty big impact on our overall gross margin. Okay. Got it. Thanks for that. Then I guess my follow-up, Mike, just on kind of the levers for growth going forward, you know, maybe I forgot about this, but I don't remember you kind of highlighting allogeneic specifically. You know, obviously that's a big opportunity for the industry. I'm just kind of curious, as we think about allogeneic therapies and maybe some of your key offerings like media, EVO, and freezers, how does the opportunity for an allogeneic therapy compare to an autologous across those lines? Yeah. Thanks, Jacob. Super question. It will be significant. We firmly believe that there will be an eventual shift to predominant allogeneic therapies as more biology is understood, and, you know, the infrastructure to support massive production of doses that can be administered to unrelated recipients, relative to the donor gets all flushed out in the system. You know, that's certainly an upside lever and a catalyst for us that we think is gonna be meaningful. I'll just remind our listeners that we are involved in the leading allogeneic cell therapy developers today, and you've heard me mention some of those names. Again, a good lever for us. As far as, you know, when that's gonna happen, nobody really has the best crystal ball, but we have the shots on goal there, so we're gonna continue to support those customers. At some point. You know, some number of those, a meaningful number, are going to get approval, and then we're gonna see that manufactured dose count skyrocket relative to what the total combined global production of autologous cell therapies is, at least in the current timeframe, right? Got it. Thanks for taking the question. It's Mike. Thank you, Jacob. We'll take our next question from Yuan Zhi with B. Riley. Thank you for taking our questions. Good afternoon, Mike and Troy. Maybe one follow-up on Jacob's question. How should we understand the path of average 2 points improvement per quarter? Does it mean that you can achieve 40% adjusted margin by year-end 2023 and another 10% improvement in 2024? Just, some additional color will be very helpful. Thank you. Yeah. Good, good question, Yuan. We would encourage people not to try to linearize that in terms of margin improvement because some of those things will be large step changes based on the new revenue streams, so new products and new services. We don't give, obviously, quarterly guidance when that's going to happen, but we would discourage people from trying to just annualize that and then break it down into four chunks of two points a piece. That's not the way we're thinking about it internally here, okay? Yeah, got it. Yeah. Then for your 2023 growth, thank you for putting out the chart of the new customer acquisition in 4Q 2022. Just want to hear, do you attribute your 2023 growth to growing demand from existing customers versus, you know, acquisition of new customers? Yeah, good question, Yuan. more weighted toward growth with existing customers, you know, as that book of revenue is spread out amongst, you know, that fixed overhead that supports that. those new customers are great, there are seeds being planted, but they're not that meaningful in their early years until they get to later stages of development. most of the revenue comes from existing customers, and we're obviously doing all we can to sell more to those existing customers to get deeper, while not obviously taking our eye off the ball with nurturing those nascent customers, some of which are gonna grow up to be, you know, the meaningful customers of tomorrow in the next year as they make it across the goal line and their own therapies are commercialized. Yeah, got it. One last question from us. As you may have seen, Legend and Johnson & Johnson paused their U.K. launch of their CAR T product due to, you know, the supply chain stress. Understand different cell and gene therapy service providers have different exposure to each CAR T product. Just want to hear how this would impact your 1Q 2023 and 2023 revenue, full year revenue. Of course, we are only a few days away from 2Q, so 1Q might be less impacted in terms of forecasts. Yeah, fair question, Yuan, but I'll just say that we don't speak about particular customers on a revenue basis. I will say that, just generally, that news from Legend and Janssen, it's not impacting our view of how this year is going to turn out. I'll leave it at that, okay? Yeah. Thanks for taking our questions. Sure. We'll take our next question from Max Masucci with TD Cowen. Hi, this is Stephanie on for Max. Thanks for taking my questions. Congrats on a great year. Hey, Stephanie. Thank you. Stephanie. Thank you. Yeah, of course. Starting off, last quarter, you indicated some supply chain constraints in both your cell processing and freezers segment. How much did supply chain constraints affect Q4 performance in these segments, and what are your expectations for the constraints in 2023? Yeah. I think I'll answer the last part first. We made some significant improvements in sourcing tanks and for freezers, but also a new bag supplier on the media side in cell processing, which will hopefully reduce the scrap that we've been experiencing for the last several quarters in a row now. The bag supplier we currently have is a world-class company, but the bag itself is not particularly certified as particulate-free. We're having to throw a fair amount of bags away because they do have particulates in them, despite the supplier's best efforts, and obviously, our own internal inspection is completely rigid and robust about that. The new supplier that's coming online we think will have a meaningful impact in reducing scrap and then improving gross margin within the already high-margin cell processing line itself. As far as, in the quarter, in Q4, there certainly was some scrap that Troy had mentioned, whether it's talking about bags or we had some scrap in the EVO line, we had some scrap in the freezer line as well. Got it. That's helpful color. For 2023, you guided cell processing revenues to grow 30%-35% year-over-year, which compares to the 52% growth we saw in 2022. Is there a decent amount of conservatism baked in here, and are there any potential sources of upside that you can highlight for the year? Yeah. Appreciate you, appreciate you noticing that. That's an anticipated question on our side. Yes, indeed, we are conservative by nature. Our goal is to meet or slightly beat and not have bad surprises. There could be some upside that we would speak to, but, you know, I'll just say generally and not speak about specific customers in that regard. We're obviously keeping a really close eye on, you know, the five anticipated approvals this year and the five for next year. You know, really paying attention to those customers and working with their procurement teams to make sure that we've got good forecasts and plenty of inventory to take care of them. Got it. That's helpful. If I could just squeeze in one more. You indicated a goal to reach 70% recurring high margin revenues of total revenues in 2025. What are the steps that you're taking to increase that higher margin recurring revenue stream? What catalyst should we be looking for to monitor your progress? Yeah, good question. You know, we're already at about 60 now, so it's 10 percentage points of improvement to get there, to have 70% recurring high margin or disposable consumable, call it what you want. That will be driven from, you know, obviously this, the de novo growth in cell processing from the current customers and then the additional customers that are in late stage and, you know, between now and then, some of them getting approved and kicking in to becoming meaningful revenue contributors. Also some of the new products and services as it relates to accessories and other non-instrument product and service lines that we've got in development right now. We'd just love to tell everybody in the call a lot of those details, but obviously, for competitive reasons, we'll hold that fire till it's time. Got it. Thanks again for taking my questions. You're welcome. We'll take our next question from Thomas Flaten with Lake Street Capital Markets. Hey, guys. Appreciate you taking the questions. As we look, you know, kinda as you're exiting 2024, Mike, I'm curious about the geographic distribution of revenues. Do you anticipate there being any significant shift from the way the revenues are distributed today? Yeah, really good question, Thomas. Yes, I would say that, we would look for a much more meaningful contribution from Asia-Pacific compared to where it is now, relatively speaking. Yep. Can you talk a little bit about, you know, what parts of the business or maybe it's all will contribute to that shift over to Asia? I'll just speak mostly about channels, right? About direct and indirect and compared to what we have today in terms of a very modest number of feet on the street and a lot of distributors, and then our efforts to rationalize that network of distributors in APAC to make sure we've got the most productive, the most technically fluent from a sales perspective, most productive distributors carrying our solutions. That's the stuff we're focused on. Got it. Just one quick one on cross-selling. Is there a particular direction from which cross-selling has been most meaningful? Is it media customers buying freezers, or maybe it's freezer customers buying media? I'm just curious if you could characterize that a little bit for us. Yeah, I'll try. The obvious one is within cell processing, the highest affinity is between the biopreservation media and the Sexton media vials and film machines because those are opportunities where it's the exact same call point, decision-maker, influencer base amongst those two parts of that platform. I would draw some parallels to between freezers and our storage services because, you know, and it's a benefit that we have now that in today's capital equipment environment with some projects being delayed, we can, in the same conversation, offer to the customer or the prospect to store their biological material for them in our freezers in our facilities, as opposed to just kinda having to walk away with our hat in our hand saying, "Well, okay, give me a call if your cash gets freed up, and you can place the order for freezers." That's another one that we're really focused on. Got it. Appreciate you taking the questions. Thank you. Thank you, Thomas. As a reminder, everyone, that is star one to ask a question. We'll pause for a moment. All right. There are no further questions. I would like to turn the call back over to Mike Rice for any additional or closing comments. Thank you, Lisa. Thanks again, everyone, for your interest in BioLife. We hope you have a great evening, and we look forward to seeing many of you next week at our Analyst and Investor Day in Boston. Good night. That does conclude today's presentation. Thank you for your participation, and you may now disconnect.